SecBot SecBot
425 ·Filed Oct 26, 2026

AMAN

Amanat Acquisition Corp.
NEUTRAL
Impact 5/10
Processed1h 4m ago SEC0001213900-26-112239
Rule 425 M&A communications

Price Chart

Loading chart...

Documents Analyzed

This report is based on 2 SEC documents filed with EDGAR.

DocumentAccession Number
425 Filing (Primary)0001213900-26-112239
Document: ea030895401ex10-2.htm0001213900-26-112239
10 reports for AMAN
Performance horizon
Filters
Rows
Reports for AMAN — sortable, filterable
TypeNow
Oct 26, 2026
today
425
NEUTRAL ★ 5/10
—awaiting T+20——
Oct 26, 2026
today
8-K
NEUTRAL ★ 6/10
$10.39awaiting T+20—$10.22 (−1.64%)
May 27, 2026
21w ago
8-K
NEUTRAL ★ 3/10
$10.14 $10.08▼ −0.59%▲ +2.55%$10.22 (+0.79%)
May 21, 2026
22w ago
8-K
NEUTRAL ★ 5/10
$10.13 $10.08▼ −0.54%▼ −0.88%$10.22 (+0.89%)
May 19, 2026
22w ago
424B4
NEUTRAL ★ 4/10
$10.10 $10.08▼ −0.20%▼ −0.94%$10.22 (+1.19%)
May 19, 2026
22w ago
3
NEUTRAL ★ 1/10
$10.10 $10.08▼ −0.20%▼ −0.94%$10.22 (+1.19%)
May 19, 2026
22w ago
3
NEUTRAL ★ 2/10
$10.10 $10.08▼ −0.20%▼ −0.94%$10.22 (+1.19%)
May 19, 2026
22w ago
3
NEUTRAL ★ 2/10
$10.10 $10.08▼ −0.20%▼ −0.94%$10.22 (+1.19%)
May 19, 2026
22w ago
Press Release
NEUTRAL ★ 4/10
$10.01 $10.08▲ +0.70%▼ −0.29%$10.22 (+2.10%)
May 14, 2026
23w ago
S-1/A
NEUTRAL ★ 4/10
—awaiting T+20——
Showing 10 of 10

US Market Status

Market Closed — Opens in 2h 10m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Oct 26, 2026

Fresh AMAN Intelligence

Analysis is for subscribers only.

Amanat Acquisition Corp. (SPAC) has entered into a definitive Business Combination Agreement to acquire Corxel Pharmaceuticals, a biopharmaceutical company developing oral small-molecule GLP-1 RA, amylin RA, aldosterone synthase inhibitor and other programs. The transaction values Corxel at an…

Subscribe for Full Access